Adracard develops an accessible and easy-to-use adrenaline delivery system designed to mitigate the practical barriers associated with current anaphylaxis treatments. This solution aims to minimize delayed or absent adrenaline administration, which is crucial for mitigating severe allergic reactions. The company focuses on improving patient adherence and quality of life by offering a more stable and user-friendly auto-injector alternative.
Funding
Funding not disclosed
Founders
Product
Problem
Current epinephrine auto-injectors for anaphylaxis treatment face challenges such as bulkiness, short shelf life, temperature instability, and needle phobia, leading to reluctance in patients to carry or administer the medication when needed. This can result in delayed treatment and increased risk of severe outcomes during an anaphylactic reaction.
Solution
Adracard is developing a compact, needle-free epinephrine delivery system designed to overcome the limitations of traditional auto-injectors and improve patient compliance. The device aims to provide a more accessible, easy-to-use, and stable treatment option for individuals at risk of anaphylaxis. By addressing the key barriers to epinephrine administration, Adracard seeks to minimize delays in treatment, reduce avoidable hospitalizations, and improve the quality of life for anaphylaxis sufferers. The company's vision is to eliminate the burden of anaphylaxis treatment through innovative solutions.
Target Audience
The primary target audience includes individuals with allergies at risk of anaphylaxis, their caregivers, and healthcare providers seeking improved epinephrine delivery solutions.
Features
- Needle-free delivery system for epinephrine administration
- Compact and portable design for convenient carrying
- Enhanced stability to withstand harsh environmental conditions
- User-friendly design for easy and rapid self-administration